Personalized medicine
The California-based company will use the funds to expand its Whole Body Twin Technology, aimed at preventing and reversing metabolic disease.
CellFE, a tech-enabled cell engineering platform, and Plenful, a workflow-automation platform for pharmacy operations, also garnered investment.
The Japanese manufacturer's new company, established in Delaware, will utilize a cell picking and imaging system to help providers detect and treat diseases.
The company will use the funds to enrich its technology, commercialize its MRD product and continue the development of its multi-cancer early detection offering.
The company will use the funds to expand its value-based cancer care network and extend its reach with health plans, employers and providers.
The life sciences company's Gut Intelligence Test will be available in 200 CVS locations and through the drugstore chain online.
The partnership will allow Molina's Virginia-based Medicare and healthcare marketplace members access to culturally competent maternal health experts.
The purchase comes on the heels of the surgical navigation platform's $82.5 million Series D raise in June.
The company will use the investment to fuel the expansion of Paradigm,its FDA-cleared, AI-enabled surgical navigation platform.
The multiple sclerosis-focused company will use the funds to speed up the company's commercialization efforts.